Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$629K Sell
26,129
-684
-3% -$17.9K 0.27% 68
2026
Q1
$753K Sell
26,813
-694
-3% -$18.5K 0.36% 59
2025
Q4
$685K Sell
27,507
-2,642
-9% -$66.6K 0.43% 53
2025
Q3
$768K Sell
30,149
-940
-3% -$23.2K 0.4% 53
2025
Q2
$754K Sell
31,089
-318
-1% -$7.42K 0.39% 53
2025
Q1
$796K Buy
31,407
+6,031
+24% +$158K 0.44% 47
2024
Q4
$673K Sell
25,376
-13,321
-34% -$361K 0.35% 63
2024
Q3
$1.12M Sell
38,697
-1,501
-4% -$43.8K 0.6% 39
2024
Q2
$1.12M Sell
40,198
-894
-2% -$24.6K 0.65% 36
2024
Q1
$1.14M Buy
41,092
+1,606
+4% +$44.6K 0.69% 36
2023
Q4
$1.14M Buy
+39,486
New +$1.19M 0.75% 36

Other funds holding PFE

ELCO Management's PFE Position: Q2 2026 in Review

ELCO Management reduced its Pfizer (PFE) stake by 2.6% in Q2 2026, selling an estimated $17.9K and leaving 26,129 shares worth $629K. The position accounts for 0.27% of the portfolio, ranked #68.

ELCO Management first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.14M in Q1 2024. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • ELCO Management held 26,129 shares of Pfizer worth $629K as of Q2 2026.
  • ELCO Management sold 684 Pfizer shares in Q2 2026, an estimated $17.9K.
  • Pfizer made up 0.27% of ELCO Management's portfolio in Q2 2026, its #68 holding.
  • ELCO Management first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • ELCO Management's Pfizer position peaked at $1.14M in Q1 2024.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on ELCO Management's 13F filing for Q2 2026, filed 11 Aug 2026.